Importance of Diagnosis in Breast Cancer with Non-BRCA Pathogenic Germline Variants of Cancer Susceptibility Genes using High-Throughput Sequencing Analysis
Objectives: The aim was to point out the importance of the diagnosis rate of breast cancer (BC) by analyzing the cancer predisposition genes except BRCA1/2 with multigene testing.
Methods: In this study, 232 non-BRCA cases with BC and/or BC family history (FH) were analyzed using the next-generation sequencing method.
Results: Twenty-two different pathogenic/likely pathogenic variants were determined in 24 (10.34%) of cases, and these variants were detected in the CHEK2 (7/24, 29.1%), ATM (5/24, 20.8%), MUTYH (3/24, 12.5%), BLM (2/24, 8.3%), WRN (2/24, 8.3%), TP53 (1/24, 4.1%), BRIP1 (1/24, 4.1%), MSH2 (1/24, 4.1%), NBN (1/24, 4.1%), and PTEN (1/24, 4.1%) genes including three novel variants which were identified in the BLM, ATM, and MSH2 (3/22, 13.6%) genes. Fourteen of 24 (58.3%) cases had BC diagnosis, and 10 of 24 (41.6%) cases had a FH of BC.
Conclusion: Among non-BRCA BC and/or BC FH cases, cancer susceptibility gene frequency was 10.34% in this study. CHEK2 and ATM genes had relatively high mutation rates.
1. Reiner AS, Sisti J, John EM, Lynch CF, Brooks JD, Mellemkjær L, et al; WECARE Study Collaborative Group. Breast cancer family history and contralateral breast cancer risk in young women:
an update from the women's environmental cancer and radiation epidemiology study. J Clin Oncol 2018;36:1513–20. 2. Boujemaa M, Hamdi Y, Mejri N, Romdhane L, Ghedira K, Bouaziz H, et al. Germline copy number variations in BRCA1/2 negative families: Role in the molecular etiology of hereditary BC in Tunisia. PLos One 2021;16:e0245362.
3. Ronowicz A, Janaszak-Jasiecka A, Skokowski J, Madanecki P, Bartoszewski R, Bałut M, et al. Concurrent dna copy-number alterations and mutations in genes related to maintenance of genome stability in uninvolved mammary glandular tissue from BC Patients. Hum Mutat 2015;36:1088–99.
4. Tynan M, Peshkin BN, Isaacs C, Willey S, Valdimarsdottir HB, Nusbaum R, et al. Predictors of contralateral prophylactic mastectomy in genetically high risk newly diagnosed breast cancer patients. Breast Cancer Res Treat 2020;180:177–85.
5. Huber D, Seitz S, Kast K, Emons G, Ortmann O. Use of fertility treatments in BRCA1/2 mutation carriers and risk for ovarian and BC: a systematic review. Arch Gynecol Obstet 2020;302:715–20.
6. Lang GT, Shi JX, Huang L, Cao AY, Zhang CH, Song CG, et al. Multiple cancer susceptible genes sequencing in BRCA-negative BC with high hereditary risk. Ann Transl Med 2020;8:1417.
7. Hu C, Hart SN, Gnanaolivu R, Huang H, Lee KY, Na J, et al. A population-based study of genes previously ımplicated in breast cancer. N Engl J Med 2021;384:440–51.
8. Ki CS. Recent advances in the clinical application of next-generation sequencing. Pediatr Gastroenterol Hepatol Nutr 2021;24:1–6.
9. den Dunnen JT, Dalgleish R, Maglott DR, Hart RK, Greenblatt MS, McGowan-Jordan J, et al. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat 2016;37:564–9.
10. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of
Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405–24. 11. Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res 2018;46:1062–7.
12. Stewart SL, King JB, Thompson TD, Friedman C, Wingo PA. Cancer mortality surveillance--United States, 1990-2000. MMWR Surveill Summ 2004;53:1–108.
13. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001;358:1389–99.
14. Özmen V. Breast cancer in Turkey: Clinical and histopathological characteristics (analysis of 13.240 patients). J Breast Health 2014;10:98–105.
15. Hu C, Polley EC, Yadav S, Lilyquist J, Shimelis H, Na J, et al. The contribution of germline predisposition gene mutations to clinical subtypes of invasive breast cancer from a clinical genetic testing cohort. J Natl Cancer Inst 2020;112:1231–41.
16. US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, et al. Risk Assessment, genetic counseling, and genetic testing for BRCA-related cancer: US Preventive Services Task Force recommendation statement. JAMA 2019;322:652–65.
17. Germani A, Petrucci S, De Marchis L, Libi F, Savio C, Amanti C, et al. Beyond BRCA1 and BRCA2: Deleterious variants in DNA repair pathway genes in Italian families with breast/ovarian and pancreatic cancers. J Clin Med 2020;9:3003.
18. Schubert S, van Luttikhuizen JL, Auber B, Schmidt G, Hofmann W, Penkert J, et al. The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants. Int J Cancer 2019;144:2683–94.
19. Gomes R, Spinola PDS, Brant AC, Matta BP, Nascimento CM, de Aquino Paes SM, et al. Prevalence of germline variants in consensus moderate-to-high-risk predisposition genes to hereditary breast and ovarian cancer in BRCA1/2-negative Brazilian patients. Breast Cancer Res Treat 2021;185:851–61.
20. Zanti M, Loizidou MA, Michailidou K, Pirpa P, Machattou C, Marcou Y, et al. NGS panel testing of triple-negative breast cancer patients in Cyprus: A study of BRCA-negative cases. Cancers (Basel) 2020;12:3140.
21. Maxwell KN, Wubbenhorst B, D'Andrea K, Garman B, Long JM, Powers J, et al. Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer. Genet Med 2015;17:630–8.
22. Felicio PS, Grasel RS, Campacci N, de Paula AE, Galvão HCR, Torrezan GT, et al. Whole-exome sequencing of non-BRCA1/ BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer. Hum Mutat 2021;42:290–9.
23. Hauke J, Horvath J, Groß E, Gehrig A, Honisch E, Hackmann K, et al. Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. Cancer Med 2018;7:1349–58.
24. Fan Z, Hu L, Ouyang T, Li J, Wang T, Fan Z, et al. Germline mutation in DNA-repair genes is associated with poor survival in BRCA1/2-negative breast cancer patients. Cancer Sci 2019;110:3368–74.
25. Stolarova L, Kleiblova P, Janatova M, Soukupova J, Zemankova P, Macurek L, et al. CHEK2 Germline variants in cancer predisposition: stalemate rather than checkmate. Cells 2020;9:2675.
26. Tan Y, Raychaudhuri P, Costa RH. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol Cell Biol 2007;27:1007–16.
27. Grignol VP, Agnese DM. BC genetics for the surgeon: an update on causes and testing options. J Am Coll Surg 2016;222:906– 14.
28. Koldehoff A, Danner M, Civello D, Rhiem K, Stock S, Müller D. Cost-effectiveness of targeted genetic testing for breast and ovarian cancer: a systematic review. Value Health 2021;24:303–12.